Production (Stage)
Altamira Therapeutics Ltd.
CYTOF
$0.10
$0.00060.60%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | 27.00% | 27.00% | -- |
| Total Depreciation and Amortization | -- | -- | -7.03% | -7.03% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | -41.23% | -41.23% | -- |
| Change in Net Operating Assets | -- | -- | 111.89% | 111.89% | -- |
| Cash from Operations | -- | -- | 62.00% | 62.00% | -- |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 200.00% | 200.00% | -- |
| Cash from Investing | -- | -- | 200.00% | 200.00% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 57.61% | 57.61% | -- |
| Issuance of Common Stock | -- | -- | -56.12% | -56.12% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 68.98% | 68.98% | -- |
| Cash from Financing | -- | -- | -70.11% | -70.11% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -64.31% | -64.31% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | -1,822.16% | -1,822.16% | -- |